荃信生物拟配售500万股H股：筹资近1亿港元，加速自免双抗等关键研发进展

Core Viewpoint - The article discusses the recent share placement by Qianxin Biotech, highlighting its significant stock price increase of 240% this year and the strategic use of the raised funds for debt repayment and R&D [2][3]. Group 1: Share Placement Details - On August 18, Qianxin Biotech announced a conditional placement agreement with CICC to issue 5 million new H-shares at HKD 20.0 per share, raising approximately HKD 99 million [2]. - The placement price represents a discount of 10.95% compared to the closing price of HKD 22.46 on August 15, but is at a premium of 9.11% over the average price of HKD 18.33 over the past 30 days [2][3]. - The shares being placed account for about 2.25% of the total issued H-shares, increasing the total share capital from 222,071,600 to 227,071,600 shares [2]. Group 2: Fund Utilization - Approximately 60% (around HKD 59.4 million) of the raised funds will be used to repay bank loans incurred due to increased R&D investments, aiming to reduce the asset-liability ratio and financial costs [3][4]. - About 30% (approximately HKD 29.7 million) will be allocated to the preclinical and early clinical research of three new pipelines: QX027N, QX031N, and QX035N [4]. - The remaining 10% (around HKD 9.9 million) will be used for general working capital and corporate purposes [4]. Group 3: Company Performance and Pipeline - As of August 15, Qianxin Biotech reported a 356.7% year-on-year increase in revenue to HKD 206 million, with a significant reduction in losses by 96.1% to HKD 5.22 million, and cash reserves of HKD 559 million [4]. - The company focuses on biotherapies for autoimmune and allergic diseases, with clinical and preclinical projects covering four major therapeutic areas: skin, respiratory, digestive, and rheumatology [5]. - Qianxin Biotech has disclosed four innovative dual-antibody pipelines, with three (QX027N, QX031N, and QX035N) expected to file for IND this year [5].